Can you please point me to a Phase 1b or Phase 2 trial that has hundreds if not thousands of patients? Can you also please point me to breakthrough therapy trials that have not been subject to careful FDA scrutiny regarding safety and efficacy first? I think you would be better pointing your comments at the big pharma executives that have failed recognise the potential of Imugene rather than the executives of IMU that are, no doubt, pushing the field of immuno-oncology forward every day including on the commercial side of the equation.@eesuper
WMHB Response Enhertu - over 1,000 patients in recent years - I can cite several other examples, of that and FDA approval and Big Phjarma funding, but do I need to
Enhertu (Dachyo Sankyo) reaches a deal with Astra Zeneca for 7bn USD - Imugene
pays business personnel cash bonuses for no deal. Meanwhile Astra Zeneca progresses trials with close to 1,00 patients in breast and lung cancer indication with Imugene yet to enrol 100 patients in their Her 2 competitor Her Vaxx. Meanwhile cash bonuses continue to pay cash bonuses to staff employed for the purpose of securing supply agreements
Can you please point me to a Phase 1b or Phase 2 trial that has...
-
- There are more pages in this discussion • 8,197 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
-0.004(7.55%) |
Mkt cap ! $371.8M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.3¢ | 4.9¢ | $755.6K | 14.97M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 36 | 4097999 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 2519184 | 28 |
View Market Depth
| Last trade - 12.36pm 15/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |